Nuwiq® is indicated for the treatment and prophylaxis of bleeding in persons with hemophilia of all ages suffering with hemophilia A (congenital factor VIII deficiency). Nuwiq® can also be used in hemophilia A patients undergoing major or minor surgical procedures.
Nuwiq®
Nuwiq is used for the treatment and prophylaxis of bleeding in adults and children of all ages with hemophilia A (congenital factor VIII deficiency). Hemophilia is a bleeding disorder in which a person’s blood does not clot properly. Hemophilia A is the result of a deficiency of factor VIII (FVIII) protein, this protein is necessary to allow the proper formation of a clot to stop bleeding.
Hemophilia A can be treated by giving factor VIII concentrate to replace the deficient factor and raise the levels of FVIII. This helps the blood to clot. Nuwiq is a coagulation factor concentrate made by recombinant technology, and its medicinal ingredient is antihemophilic Factor (Recombinant, B-Domain deleted).